Sonoma Pharmaceuticals
SNOA
16 hedge funds and large institutions have $396K invested in Sonoma Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 6 closing their positions.
72% more capital invested
Capital invested by funds: $230K → $396K (+$166K)
2.79% more ownership
Funds ownership: 3.61% → 6.4% (+2.8%)
20% less funds holding
Funds holding: 20 → 16 (-4)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$162K |
| 2 |
MCWS
McKinley Carter Wealth Services
Wheeling,
West Virginia
|
+$41.3K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.84K |
| 4 |
GRP
Global Retirement Partners
San Rafael,
California
|
+$1.23K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.33K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$6.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.25K |
| 4 |
Citigroup
New York
|
-$2.54K |
| 5 |
Rockefeller Capital Management
New York
|
-$2.51K |
SNOA Hedge Fund Activity: Q4 2025 in Review
16 of the 8,245 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q4 2025, worth a combined $396K — up 72% from $230K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SNOA and 2 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 3 added.
The largest buyer was DRW Securities, adding an estimated $162K. The largest seller was Vanguard Group, cutting an estimated $7.33K.
- 16 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q4 2025, down from 20 in Q3 2025.
- Funds reported $396K of Sonoma Pharmaceuticals stock for Q4 2025, up 72% quarter-over-quarter.
- 2 funds opened new Sonoma Pharmaceuticals positions in Q4 2025 and 6 closed out, a net change of -4 holders.
- The largest Sonoma Pharmaceuticals buyer in Q4 2025 was DRW Securities, an estimated $162K added.
- The largest Sonoma Pharmaceuticals seller in Q4 2025 was Vanguard Group, an estimated $7.33K sold.
Based on aggregated 13F filings for Q4 2025.